7.875

3.00% 0.215

Aurinia Pharmaceuticals Inc (AUPH)

Overview News Price History Option Chain Financials Why AUPH Down? Discussions Forecast Stock Split

Aurinia Pharmaceuticals Inc stock is traded at $7.875, with a volume of 658.84K. It is up +3.00% in the last 24 hours and down -6.52% over the past month. Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Previous Close:

$7.66

Open:

$7.77

24h Volume:

658.84K

Relative Volume:

0.50

Market Cap:

$1.06B

Revenue:

$175.51M

Net Income/Loss:

$-78.02M

P/E Ratio:

-14.86

EPS:

-0.53

Net Cash Flow:

$-34.18M

1W Performance:

+1.81%

1M Performance:

-6.52%

6M Performance:

+11.60%

1Y Performance:

+56.24%

1-Day Range:

$7.75

$7.915

1-Week Range:

$7.59

$7.915

52-Week Range:

$4.77

$10.67

Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile

Name

Aurinia Pharmaceuticals Inc

Sector

Healthcare (1155)

Industry

Biotechnology (677)

Phone

250-744-2487

Address

#140, 14315 - 118 AVENUE, EDMONTON, BC

Employee

300

Twitter

@AuriniaPharma

Next Earnings Date

2024-11-07

Latest SEC Filings

AUPH's Discussions on Twitter

Compare AUPH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AUPH Aurinia Pharmaceuticals Inc	7.875	1.06B	175.51M	-78.02M	-34.18M	-0.53
VRTX Vertex Pharmaceuticals Inc	489.69	128.67B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	583.23	60.99B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	600.69	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	236.00	29.89B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	254.09	26.16B	3.81B	-644.79M	-669.77M	-6.24

Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-04-22	Downgrade	Oppenheimer	Outperform → Perform
May-05-22	Resumed	Cantor Fitzgerald	Overweight
Dec-10-21	Upgrade	Oppenheimer	Perform → Outperform
Oct-28-21	Downgrade	Oppenheimer	Outperform → Perform
Jan-25-21	Reiterated	H.C. Wainwright	Buy
Nov-03-20	Reiterated	H.C. Wainwright	Buy
Jun-17-20	Initiated	BTIG Research	Buy
May-05-20	Initiated	Cowen	Outperform
Jan-10-20	Initiated	Jefferies	Buy
Dec-16-19	Reiterated	H.C. Wainwright	Buy
Mar-16-18	Reiterated	Cantor Fitzgerald	Overweight
Feb-08-18	Initiated	RBC Capital Mkts	Outperform
Oct-30-17	Reiterated	H.C. Wainwright	Buy
May-18-17	Reiterated	H.C. Wainwright	Buy
Apr-11-17	Initiated	Cantor Fitzgerald	Overweight
Mar-22-17	Reiterated	FBR & Co.	Outperform
Dec-30-16	Reiterated	H.C. Wainwright	Buy
Aug-17-16	Reiterated	H.C. Wainwright	Buy
Jun-30-16	Initiated	H.C. Wainwright	Buy
May-08-15	Initiated	MLV & Co	Buy

View All

Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News

Apr 19, 2025

Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet - MSN

Apr 19, 2025

Apr 17, 2025

Aurinia Sues Galenicum to Block Copies of Lupkynis Kidney Drug - Bloomberg Law News

Apr 17, 2025

Apr 11, 2025

Aurinia Sues Lotus Alleging Lupus Drug Patent Infringement - Law360

Apr 11, 2025

Apr 07, 2025

High Growth Tech Stocks To Watch In The US Market - simplywall.st

Apr 07, 2025

Apr 02, 2025

Declining Stock and Decent Financials: Is The Market Wrong About Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)? - Yahoo

Apr 02, 2025

Apr 01, 2025

Little Excitement Around Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Revenues - simplywall.st

Apr 01, 2025

Mar 25, 2025